Vanta Bioscience Ltd — Results, 01-08-2025: Result

Vanta Bioscience Limited's Board has approved the audited standalone and consolidated financial results for the half-year and full-year ended March 2025. For the full year, standalone revenue stood at ₹1.13 Cr, with a net loss of ₹2.66 Cr. On a consolidated basis, the company reported ₹1.96 Cr in revenue and a net loss of ₹4.77 Cr. The consolidated results' approval was delayed due to the late receipt of accounts from an Associate Company. The statutory auditors have issued an unmodified opinion on both the standalone and consolidated financial statements, indicating a clear audit report.